The Emergence of Oral Therapy as a Pillar of Care in B-Cell Lymphoma: Insights and Expert Opinions From the Hematology-Oncology Team


Manage episode 238145162 series 9912
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, hematology and oncology experts discuss the emergence of novel, orally administered therapeutics as management options for patients with B-cell lymphoma. This activity also features the perspectives of a patient with small lymphocytic lymphoma and his experience of oral therapy during the course of his therapeutic journey. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data on novel oral agent classes, including BTK and PI3K inhibitors, and immunomodulators, for B-cell non-Hodgkin lymphomas (NHLs) such as CLL, MCL, WM, and other indolent or aggressive B-cell malignancies, Apply optimal strategies to educate patients on therapeutic expectations, and adherence and safety issues regarding oral treatment regimens for B-cell NHL, Collaborate with other members of the hematology-oncology team to manage dosing and develop effective side effect prevention and management strategies in patients with B-cell NHL receiving oral therapies.

276 episodes available. A new episode about every 3 days averaging 58 mins duration .